Implementation Benchmark of Tumor-Agnostic Eligibility Signals Across Routine Comprehensive Genomic Profiling Platforms in Japan: A Nationwide C-CAT Analysis
Current Oncology · 30.05.2026 · 33 (6) · 324
DOI: 10.3390/curroncol33060324 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Oncology, online erschienen am 30.05.2026. Verfasst von Shinya Kajiura und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Toyama, Japan. Hauptthemen laut MEDLINE: Genomics, Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Routine precision oncology requires realistic benchmarks for tumor-agnostic eligibility signals observed in heterogeneous comprehensive genomic profiling (CGP) pathways. We performed a retrospective descriptive analysis of anonymized aggregated nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) data in Japan, including 97,343 CGP-tested cases summarized across five routine CGP platforms and categorized into 12 prespecified organ groups for analysis. The primary strict approved set endpoint was the case-level union of MSI-H, TMB-H, NTRK fusion/rearrangement, RET fusion/rearrangement, and ERBB2 amplification; the expanded practical set endpoint additionally included ALK fusion/rearrangement and BRAF V600E. The primary strict approved set endpoint was observed in 14,005 cases (14.4%), and the expanded practical set endpoint in 15,911 cases (16.3%), adding 1906 cases and increasing the observed rate by 2.0 percentage points. Signals varied across organ groups and platform/specimen contexts. TMB-H and ERBB2 amplification numerically dominated the primary set signal, whereas NTRK and RET fusion/rearrangement remained rare. These observed frequencies should be interpreted as case-level implementation signals surfaced through routine CGP rather than assay superiority evidence, biological prevalence estimates, or treatment-benefit data. This nationwide, platform-aware benchmark supports practical interpretation of tumor-agnostic eligibility signals in routine CGP practice in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology and Palliative Medicine, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Toyama, Japan.
ORCID-Profile: Shinya Kajiura, Ryuji Hayashi
Zitieren
APA
Kajiura, S., Nakamura, N., & Hayashi, R. (2026). Implementation Benchmark of Tumor-Agnostic Eligibility Signals Across Routine Comprehensive Genomic Profiling Platforms in Japan: A Nationwide C-CAT Analysis. Current Oncology, 33(6), 324. https://doi.org/10.3390/curroncol33060324
Vancouver
Kajiura S, Nakamura N, Hayashi R. Implementation Benchmark of Tumor-Agnostic Eligibility Signals Across Routine Comprehensive Genomic Profiling Platforms in Japan: A Nationwide C-CAT Analysis. Current Oncology. 2026;33(6):324. doi:10.3390/curroncol33060324
BibTeX
@article{Kajiura2026,
author = {Kajiura, Shinya and Nakamura, Naohiko and Hayashi, Ryuji},
title = {Implementation Benchmark of Tumor-Agnostic Eligibility Signals Across Routine Comprehensive Genomic Profiling Platforms in Japan: A Nationwide C-CAT Analysis},
journal = {Current Oncology},
year = {2026},
volume = {33},
number = {6},
pages = {324},
doi = {10.3390/curroncol33060324}
}
EUVIMED